Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Issue 1 (26th May 2013)

• Record Type: Journal Article
• Authors: Gordon, S. C.; Yoshida, E. M.; Lawitz, E. J.; Bacon, B. R.; Sulkowski, M. S.; Davis, M.; Poordad, F.; Bronowicki, J.‐P.; Esteban, R.; Sniukiene, V.; Burroughs, M. H.; Deng, W.; Dutko, F. J.; Brass, C. A.; Albrecht, J. K.; Rajender Reddy, K.
• Is Part Of: Alimentary pharmacology & therapeutics. Volume 38:Issue 1(2013)
• Page Start: 16
• Page End: 27
• Publication Date: 2013-05-26
• Subjects: Digestive organs -- Diseases -- Treatment -- Periodicals; Digestive organs -- Effect of drugs on -- Periodicals; Gastrointestinal system -- Diseases -- Treatment -- Periodicals; Gastrointestinal system -- Effect of drugs on -- Periodicals; 615.73
• DOI: 10.1111/apt.12342
• Languages: English
• ISSNs: 0269-2813

Abstract

<abstract abstract-type="main" id="apt12342-abs-0001"> <title>Summary</title> <sec id="apt12342-sec-0001" sec-type="section"> <title>Background</title> <p>Adherence to therapeutic regimens affects the efficacy of peginterferon alfa (P) and ribavirin (R) therapy in patients with chronic hepatitis C virus genotype 1.</p> </sec> <sec id="apt12342-sec-0002" sec-type="section"> <title>Aim</title> <p>To determine if medication adherence impacts efficacy [sustained virological response (SVR)] with triple therapy that includes boceprevir (BOC) plus P/R.</p> </sec> <sec id="apt12342-sec-0003" sec-type="section"> <title>Methods</title> <p>Adherence was determined in two Phase 3 clinical studies with BOC: SPRINT‐2 (previously untreated patients) and RESPOND‐2 (patients who failed previous therapy with P/R). Adherence to the assigned duration of the dosing regimen and adherence to the three times a day (t.d.s.) dosing interval of 7–9 h for BOC were assessed by the recording of data from patients' dosing diaries and by the amount of study drug dispensed and returned.</p> </sec> <sec id="apt12342-sec-0004" sec-type="section"> <title>Results</title> <p>Most patients (63–71%) adhered to ≥80% of their assigned treatment duration and achieved SVR rates of 86–90%. In contrast, patients who adhered to <80% of their assigned treatment duration achieved SVR rates of 8–32% (<italic>P </italic>< 0.0001), particularly low in patients who failed previous therapy (SVR = 8–15%). Different rates of adherence (<60% to >80%) to the t.d.s. dosing interval (7–9 h) with BOC did not influence the SVR rates (SVR = 60–83%) with the exception of patients who failed previous treatment and adhered to <60% of the t.d.s. dosing interval with BOC (SVR = 48–50%; <italic>P</italic> = 0.005).</p> </sec> <sec id="apt12342-sec-0005" sec-type="section"> <title>Conclusions</title> <p>The achievement of an SVR is more dependent on adherence to the assigned duration of treatment than adherence to the t.d.s. dosing interval with boceprevir. Adherence to >60% of t.d.s. dosing with boceprevir is important in patients who failed previous therapy.</p> </sec> </abstract>